[1] REINEMANN C, STREHLITZ B. Aptamer-modified nanoparticles and their use in cancer diagnostics and treatment [J]. Swiss Medical Weekly, 2014, 144:w13908.
[2] ZHOU G, WILSON G, HEBBARD L, et al. Aptamers:a promising chemical antibody for cancer therapy [J]. Oncotarget, 2016, 7 (12):13446-13463.
[3] DARMOSTUK M, RIMPELOVA S, GBELCOVA H, et al. Current approaches in SELEX:an update to aptamer selection technology [J]. Biotechnol Adv, 2015, 33 (6 Pt 2):1141-1161.
[4] OZER A, PAGANO J M, LIS J T, et al. New technologies provide quantum changes in the scale, speed, and success of SELEX methods and aptamer characterization [J]. Mol Ther Nucleic Acids, 2014, 3:e183.
[5] ZHOU J, ROSSI J J. Evolution of cell-type-specific RNA aptamers via live cell-based SELEX [J]. Methods Mol Biol, 2016, 1421:191-214.
[6] LAVU P S, MONDAL B, RAMLAL S, et al. Selection and characterization of aptamers using a modified Whole-Cell Bacterium SELEX for the detection of salmonella enterica serovar typhimurium [J]. ACS Comb Sci, 2016, 18 (6):292-301.
[7] ZHU B, HERNANDEZ A, TAN M, et al. Synthesis of 2'-Fluoro RNA by Syn5 RNA polymerase [J]. Nucleic Acids Res, 2015,43 (14):e94.
[8] MEYER A J, GARRY D J, HALL B, et al. Transcription yield of fully 2'-modified RNA can be increased by the addition of thermostabilizing mutations to T7 RNA polymerase mutants [J]. Nucleic Acids Res, 2015, 43 (15):7480-7488.
[9] LAURIDSEN L H, ROTHNAGEL J A, VEEDU R N. Enzymatic recognition of 2'-modified ribonucleoside 5'-triphosphates:towards the evolution of versatile aptamers [J]. Chembiochem, 2012, 13 (1):19-25.
[10] LAPA S A, CHUDIONOV A V, TIMOFEEV E N. The toolbox for modified aptamers [J]. Mol Biotechnol, 2016,58(2):79-92.
[11] LIU B, ZHANG J, LIAO J, et al. Aptamer-functionalized nanoparticles for drug delivery [J]. J Biomed Nanotechnol, 2014, 10 (11):3189-3203.
[12] HUANG Y F, SHANGGUAN D, LIU H, et al. Molecular assembly of an aptamer-drug conjugate for targeted drug delivery to tumor cells [J]. Chembiochem,2009, 10 (5):862-868.
[13] TRINH T L, ZHU G, XIAO X, et al. A synthetic aptamer-drug adduct for targeted liver cancer therapy [J]. PLoS One, 2015, 10 (11):e0136673.
[14] YANG L, ZHANG X, YE M, et al. Aptamer-conjugated nanomaterials and their applications [J]. Adv Drug Deliv Rev, 2011, 63 (14-15):1361-1370.
[15] WANG J, ZHU G, YOU M, et al. Assembly of aptamer switch probes and photosensitizer on gold nanorods for targeted photothermal and photodynamic cancer therapy [J]. ACS Nano, 2012, 6(6):5070-5077.
[16] SHIAO Y S, CHIU H H, WU P H, et al. Aptamer-functionalized gold nanoparticles as photoresponsive nanoplatform for co-drug delivery [J]. ACS Appl Mater Interfaces, 2014, 6 (24), 21832-21841.
[17] LUO Y L, SHIAO Y S, HUANG Y F. Release of photoactivatable drugs from plasmonic nanoparticles for targeted cancer therapy [J]. ACS Nano, 2011, 5 (10):7796-7804.
[18] PALA K, SERWOTKA A, JELEN F, et al. Tumor-specific hyperthermia with aptamer-tagged superparamagnetic nanoparticles [J]. Int J Nanomed, 2014, 9(1):67-76.
[19] AZHDARZADEH M, ATYABI F, SAEI A A, et al. Theranostic MUC-1 aptamer targeted gold coated superparamagnetic iron oxide nanoparticles for magnetic resonance imaging and photothermal therapy of colon cancer [J]. Colloids Surf B Biointerfaces, 2016, 143:224-232.
[20] HE Z M, ZHANG P H, LI X, et al. Targeted DNAzyme-nanocomposite probe equipped with built-in Zn²⁺ arsenal for combined treatment of gene regulation and drug delivery [J]. Sci Rep, 2016, 6:22737.
[21] SAVLA R, TARATULA O, GARBUZENKO O, et al. Tumor targeted quantum dot-mucin 1 aptamer-doxorubicin conjugate for imaging and treatment of cancer [J]. J Controlled Release, 2011, 153 (1):16-22.
[22] TAGHAVI S, HASHEMNIA A, MOSAFFA F, et al. Preparation and evaluation of polyethylenimine-functionalized carbon nanotubes tagged with 5TR1 aptamer for targeted delivery of Bcl-xL shRNA into breast cancer cells [J]. Colloids Surf B Biointerfaces, 2016, 140:28-39.
[23] XIE X, LI F, ZHANG H, et al. EpCAM aptamer-functionalized mesoporous silica nanoparticles for efficient colon cancer cell-targeted drug delivery [J]. Eur J Pharm Sci, 2016, 83:28-35.
[24] TANG Y, HU H, ZHANG M G, et al. An aptamer-targeting photoresponsive drug delivery system using "off-on" graphene oxide wrapped mesoporous silica nanoparticles [J]. Nanoscale, 2015, 7(14):6304-6310.
[25] MOOSAVIAN S A, ABNOUS K, BADIEE A, et al. Improvement in the drug delivery and anti-tumor efficacy of PEGylated liposomal doxorubicin by targeting RNA aptamers in mice bearing breast tumor model [J]. Colloids Surf B Biointerfaces, 2016, 139:228-236.
[26] SONG X, REN Y, ZHANG J, et al. Targeted delivery of doxorubicin to breast cancer cells by aptamer functionalized DOTAP/DOPE liposomes [J]. Oncol Rep, 2015, 34 (4):1953-1960.
[27] ZHANG J, CHEN R, CHEN F, et al. Nucleolin targeting AS1411 aptamer modified pH-sensitive micelles:a dual-functional strategy for paclitaxel delivery [J]. J Controlled Release, 2015, 213:137-138.
[28] LI X, YU Y, JI Q, et al. Targeted delivery of anticancer drugs by aptamer AS1411 mediated Pluronic F127/cyclodextrin-linked polymer composite micelles [J]. Nanomedicine, 2015, 11 (1):175-184.
[29] GUO J, GAO X, SU L, et al. Aptamer-functionalized PEG-PLGA nanoparticles for enhanced anti-glioma drug delivery [J]. Biomaterials, 2011, 32 (31):8010-8020.
[30] PROW T W, YU C, HU Y, et al. Novel aptamer-nanoparticle bioconjugates enhances delivery of anticancer drug to MUC1-positive cancer cells in vitro [J]. PLoS One, 2011, 6 (9):e24077.
[31] HU X, TULSIERAM K L, ZHOU Q, et al. Polymeric nanoparticle-aptamer bioconjugates can diminish the toxicity of mercury in vivo [J]. Toxicol Lett, 2012, 208 (1):69-74.
[32] ARAVIND A, JEYAMOHAN P, NAIR R, et al. AS1411 Aptamer tagged PLGA-lecithin-PEG nanoparticles for tumor cell targeting and drug delivery [J]. Biotechnol Bioeng, 2012, 109 (11):2920-2931.
[33] LI L, XIANG D, SHIGDAR S, et al. Epithelial cell adhesion molecule aptamer functionalized PLGA-lecithin-curcumin-PEG nanoparticles for targeted drug delivery to human colorectal adenocarcinoma cells [J]. Int J Nanomed, 2014, 9(1):1083-1096.
[34] GHASEMI Z, DINARVAND R, MOTTAGHITALAB F, et al. Aptamer decorated hyaluronan/chitosan nanoparticles for targeted delivery of 5-fluorouracil to MUC1 overexpressing adenocarcinomas [J]. Carbohydr Polym, 2015, 121:190-198.
[35] ZHAO N, BAGARIA H G, WONG M S, et al. A nanocomplex that is both tumor cell-selective and cancer gene-specific for anaplastic large cell lymphoma [J]. J Nanobiotechnol, 2011, 9:2.
[36] YANG J, XIE S X, HUANG Y, et al. Prostate-targeted biodegradable nanoparticles loaded with androgen receptor silencing constructs eradicate xenograft tumors in mice [J]. Nanomedicine (Lond), 2012, 7 (9):1297-1309.
[37] ASKARIAN S, ABNOUS K, TAGHAVI S, et al. Cellular delivery of shRNA using aptamer-conjugated PLL-alkyl-PEI nanoparticles [J]. Colloids Surf B Biointerfaces, 2015, 136:355-364.
[38] TAGHDISI S M, DANESH N M, RAMEZANI M, et al. Double targeting and aptamer-assisted controlled release delivery of epirubicin to cancer cells by aptamers-based dendrimer in vitro and in vivo [J]. Eur J Pharm Biopharm, 2016, 102:152-158.
[39] ZHANG H, MA Y, XIE Y, et al. A controllable aptamer-based self-assembled DNA dendrimer for high affinity targeting, bioimaging and drug delivery [J]. Sci Rep, 2015, 5:10099.
[40] WU X, DING B, GAO J, et al. Second-generation aptamer-conjugated PSMA-targeted delivery system for prostate cancer therapy [J]. Int J Nanomed, 2011, 6:1747-1756.
[41] WU J, SONG C, JIANG C, et al. Nucleolin targeting AS1411 modified protein nanoparticle for antitumor drugs delivery [J]. Mol Pharm, 2013, 10 (10):3555-3563.
[42] GILBOA-GEFFEN A, HAMAR P, LE M T, et al. Gene knockdown by EpCAM aptamer-siRNA chimeras suppresses epithelial breast cancers and their tumor-initiating cells [J]. Mol Cancer Ther,2015, 14 (10):2279-2291.
[43] SUBRAM N, KANWAR J R, KANWAR R K, et al. EpCAM aptamer-siRNA chimera targets and regress epithelial cancer [J]. PLoS One, 2015, 10(7):e0132407.
[44] NI X, ZHANG Y, ZENNAMI K, et al. Systemic administration and targeted radiosensitization via chemically synthetic aptamer-siRNA chimeras in human tumor xenografts [J]. Mol Cancer Ther, 2015, 14 (12):2797-2804.